75 Participants Needed

Post-COVID Syndrome for Chronic Lung Issues

No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to understand why some people continue to feel short of breath and tired after recovering from a severe COVID-19 infection. It will compare individuals who had severe COVID-19 and were hospitalized with those who had mild COVID-19 and fully recovered. Suitable candidates for this trial include those who were hospitalized for severe COVID-19 and now experience ongoing lung issues.

As an unphased trial, this study offers participants the chance to contribute to important research that may enhance understanding and treatment of post-COVID-19 symptoms.

Why are researchers excited about this trial?

Researchers are excited about this trial because it aims to uncover the underlying mechanisms that contribute to chronic lung issues following severe COVID-19 infections. Unlike current treatments that mainly focus on managing symptoms like inflammation and breathing difficulties, this study seeks to identify why some people develop lasting lung problems after COVID-19. Understanding these mechanisms could lead to the development of more targeted and effective therapies in the future, potentially improving long-term outcomes for those affected by severe COVID-19.

Who Is on the Research Team?

RV

Robert Vassallo, MD

Principal Investigator

Mayo Clinic

Are You a Good Fit for This Trial?

Inclusion Criteria

For those in the Sequelae Group, you must meet certain criteria.
The severity of illness is classified as moderate (requiring up to 8L supplemental oxygen during hospitalization), severe (requiring high flow oxygen delivery of at least 8L) or critical (necessitating ICU admission and/or mechanical ventilation).
You are part of the Control Recovery Group.
See 2 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Initial Evaluation

Comprehensive clinical evaluation and symptom characterization, quantitative lung CT image analysis and pulmonary function testing, and quality of life questionnaires

2-3 months after COVID-19 diagnosis
1 visit (in-person)

Midpoint Evaluation

Continued assessment with clinical evaluations, imaging, and testing, including bronchoscopy with BAL and blood samples

6 months after COVID-19 diagnosis
1 visit (in-person)

Final Evaluation

Final comprehensive evaluation including bronchoscopy with BAL, blood samples, and quality of life assessments

12 months after COVID-19 diagnosis
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Group I: Sequelae groupExperimental Treatment5 Interventions
Group II: Recovery groupExperimental Treatment5 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Mayo Clinic

Lead Sponsor

Trials
3,427
Recruited
3,221,000+